WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/101535    International Application No.:    PCT/EP2004/005204
Publication Date: 25.11.2004 International Filing Date: 14.05.2004
Chapter 2 Demand Filed:    10.12.2004    
A61K 31/41 (2006.01), A61K 45/06 (2006.01), C07D 257/04 (2006.01)
Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH) (AE, AG, AL, AM, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GW, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MC, MD, MG, MK, ML, MN, MR, MW, MX, MZ, NA, NE, NI, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, SN, SY, SZ, TD, TG, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW only).
NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT) (AT only).
COHN, Jay, Norman [US/US]; (US) (For US Only).
GLAZER, Robert, Dean [US/US]; (US) (For US Only).
LATINI, Robert [IT/IT]; (IT) (For US Only).
MAGGIONI, Aldo, Pietro [IT/IT]; (IT) (For US Only).
TOGNONI, Gianni [IT/IT]; (IT) (For US Only)
Inventors: COHN, Jay, Norman; (US).
GLAZER, Robert, Dean; (US).
LATINI, Robert; (IT).
MAGGIONI, Aldo, Pietro; (IT).
TOGNONI, Gianni; (IT)
Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH)
Priority Data:
60/471,137 16.05.2003 US
Abstract: front page image
(EN)The invention relates to pharmaceutical compositions and a method of preventing or reducing the incidence of AF and thereby reducing the risk of morbidity and mortality in patients having symptomatic heart failure comprising administering to such patient an effective amount of valsartan, or pharmaceutically acceptable salts thereof, alone or in combination with another therapeutic agent, optionally in the presence of a pharmaceutically acceptable carrier.
(FR)La présente invention a trait à des compositions pharmaceutiques et un procédé de prévention ou de réduction de l'incidence de la fibrillation auriculaire réduisant ainsi le risque de maladie et de mortalité chez des patients souffrant d'insuffisance cardiaque symptomatique comprenant l'administration à un tel patient d'une quantité efficace de valsartan, ou les sels pharmaceutiquement acceptables de celui-ci, seul ou en combinaison avec un autre agent thérapeutique, éventuellement en présence d'un support pharmaceutiquement acceptable.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)